AdAlta expects an additional R&D Tax Incentive refund of more than A$1 million after securing approval for specified overseas work on its EW-001 CAR-T therapy. The cash benefit arrives as the company prepares for a US FDA pre-IND meeting in November.
- More than A$1 million additional FY26 R&D refund expected
- A$0.23 million first FY26 instalment already received
- Finding covers China trials, IND-enabling studies and manufacturing materials
- FDA pre-IND meeting scheduled for 4 November 2026 AEST
- Melbourne manufacturing transfer remains underway
Overseas R&D finding adds more than A$1 million
AdAlta Limited (ASX:1AD) has secured a formal Australian Government finding that could return more than A$1 million to the company for overseas research tied to EW-001, its lead CAR-T therapy for mesothelioma and other mesothelin-expressing cancers. AdAlta has already received the first FY26 R&D Tax Incentive instalment of A$0.23 million for the year ended 30 June 2026, with the larger additional refund still to be claimed.
The Advance Overseas Finding covers three areas of the EW-001 program: IND-enabling laboratory and safety studies, investigator-initiated clinical trials conducted in China, and raw materials purchased for manufacturing. The decision recognises those activities as sufficiently connected to AdAlta’s Australian R&D program and as work that could not be carried out in Australia, according to the announcement.
For a clinical-stage biotechnology company, the significance is practical rather than regulatory: the finding is expected to reduce the net cost of development by allowing eligible overseas expenditure to attract Australian R&D support. It does not, however, represent approval of EW-001, and the additional refund remains an expectation until AdAlta completes the claim process and receives the payment.
Tax support arrives before the FDA meeting
The announcement lands as AdAlta advances the Australian leg of its “East to West” strategy. The company has been progressing the Melbourne manufacturing transfer, while EW-001’s US FDA pre-IND meeting is scheduled for 4 November 2026 AEST. That meeting is expected to address the company’s pathway towards clinical development in the United States, but the filing does not disclose its likely outcome.
AdAlta says the finding validates the structure of its development model, combining work by cell therapy innovators in China with Australian manufacturing and clinical capabilities. The company also says similar support could benefit future products brought into the same pipeline, although each program would remain subject to its own eligibility tests.
EW-001’s clinical evidence remains early and comes from studies in China. AdAlta reports response rates of up to 50% and complete responses of up to 20% in relapsed or advanced mesothelioma patients, but the therapy has not received regulatory approval for commercial launch anywhere in the world. The immediate test is therefore twofold: whether the expected refund is converted into cash, and what the FDA says about the next development stage.
Bottom Line?
The tax finding improves the economics of EW-001 development, but the next material checkpoint remains the 4 November FDA meeting and the path from early Chinese data to regulated clinical testing.
Questions in the middle?
- When will AdAlta submit and receive the additional FY26 R&D refund, and what final amount will be recognised?
- What feedback will the US FDA provide on EW-001’s manufacturing package, remaining studies and proposed clinical pathway?
- Can the reported early responses in Chinese mesothelioma studies be reproduced using the manufacturing process planned for Australia?